Polyarteritis nodosa pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Sargun Walia (talk | contribs) |
Sargun Walia (talk | contribs) |
||
| Line 16: | Line 16: | ||
** Venous system. | ** Venous system. | ||
* It occurs when certain [[immune cells]] attack the affected [[arteries]]. | * It occurs when certain [[immune cells]] attack the affected [[arteries]]. | ||
* [[Inflammation]] starts in the vessel [[intima]] and results in [[fibrinoid necrosis]] by destroying the internal and external [[elastic]] [[lamina]]. | * [[Inflammation]] starts in the vessel [[intima]] and results in [[fibrinoid necrosis]] by destroying the internal and external [[elastic]] [[lamina]].<ref name="pmid123501942">{{cite journal |vauthors=Stone JH |title=Polyarteritis nodosa |journal=JAMA |volume=288 |issue=13 |pages=1632–9 |date=October 2002 |pmid=12350194 |doi= |url=}}</ref> | ||
* [[Aneurysms]] and [[thrombi]] may develop at the site of [[lesions]]. | * [[Aneurysms]] and [[thrombi]] may develop at the site of [[lesions]].<ref name="pmid160458322">{{cite journal |vauthors=Colmegna I, Maldonado-Cocco JA |title=Polyarteritis nodosa revisited |journal=Curr Rheumatol Rep |volume=7 |issue=4 |pages=288–96 |date=August 2005 |pmid=16045832 |doi= |url=}}</ref> | ||
** The lesion can weaken the vessel and can further can lead to: | |||
*** Obstruction | |||
*** Ischemia and infarction | |||
*** Rupture | |||
*** Hemorrhage | |||
* One hypothesis is that this condition is caused by [[antibodies]] against HBV, via a [[Hypersensitivity#Type_3_-_immune_complex | type IIII hypersensitivity reaction]]. | * One hypothesis is that this condition is caused by [[antibodies]] against HBV, via a [[Hypersensitivity#Type_3_-_immune_complex | type IIII hypersensitivity reaction]]. | ||
* [[Hepatitis C]] associated polyarteritis nodosa is the most common type among the [[hepatitis C]] associated [[vasculitis]] and has a severe clinical presentation.<ref name="pmid20981809">{{cite journal |author=Saadoun D, Terrier B, Semoun O, ''et al.'' |title=Hepatitis C virus-associated polyarteritis nodosa |journal=Arthritis Care Res (Hoboken) |volume=63 |issue=3 |pages=427–35 |year=2011 |month=March |pmid=20981809 |doi=10.1002/acr.20381 |url=}}</ref> | * [[Hepatitis C]] associated polyarteritis nodosa is the most common type among the [[hepatitis C]] associated [[vasculitis]] and has a severe clinical presentation.<ref name="pmid20981809">{{cite journal |author=Saadoun D, Terrier B, Semoun O, ''et al.'' |title=Hepatitis C virus-associated polyarteritis nodosa |journal=Arthritis Care Res (Hoboken) |volume=63 |issue=3 |pages=427–35 |year=2011 |month=March |pmid=20981809 |doi=10.1002/acr.20381 |url=}}</ref> | ||
| Line 23: | Line 28: | ||
* Due to [[inflammation]] of the medium to small sized [[vessels]] in PAN and the presence of impaired [[endothelial]] function, there could be direct [[endothelial cell]] activation and damage resulting from proinflammatory [[cytokines]] or [[antibodies]] (anti-endothelial cells antibodies). | * Due to [[inflammation]] of the medium to small sized [[vessels]] in PAN and the presence of impaired [[endothelial]] function, there could be direct [[endothelial cell]] activation and damage resulting from proinflammatory [[cytokines]] or [[antibodies]] (anti-endothelial cells antibodies). | ||
** These anti-endothelial cells antibodies in turn stimulate greater production of cytokines and adhesion [[molecules]] potentiating the [[inflammation]] causing more damage to the vessels <ref name="pmid12525387">{{cite journal| author=Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ et al.| title=Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. | journal=Ann Rheum Dis | year= 2003 | volume= 62 | issue= 2 | pages= 162-7 | pmid=12525387 | doi= | pmc=1754444 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12525387 }} </ref>. | ** These anti-endothelial cells antibodies in turn stimulate greater production of cytokines and adhesion [[molecules]] potentiating the [[inflammation]] causing more damage to the vessels <ref name="pmid12525387">{{cite journal| author=Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ et al.| title=Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. | journal=Ann Rheum Dis | year= 2003 | volume= 62 | issue= 2 | pages= 162-7 | pmid=12525387 | doi= | pmc=1754444 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12525387 }} </ref>. | ||
===Genetics=== | ===Genetics=== | ||
Revision as of 15:40, 9 May 2018
|
Polyarteritis nodosa Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polyarteritis nodosa pathophysiology On the Web |
|
American Roentgen Ray Society Images of Polyarteritis nodosa pathophysiology |
|
Risk calculators and risk factors for Polyarteritis nodosa pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]Cafer Zorkun, M.D., Ph.D. [4]; Haritha Machavarapu, M.B.B.S.
Overview
Pathophysiology
Pathogenesis
- Polyarteritis nodosa is a disease of unknown cause that affects arteries, the blood vessels that carry oxygenated blood to organs and tissues.
- PAN affects the medium sized arterial vessels.
- Most commonly occurs at the branching vessels and bifurcation points.
- PAN does not affect:[1]
- Large vessels like aorta.
- Capillaries
- Small arterioles.
- Venous system.
- It occurs when certain immune cells attack the affected arteries.
- Inflammation starts in the vessel intima and results in fibrinoid necrosis by destroying the internal and external elastic lamina.[2]
- Aneurysms and thrombi may develop at the site of lesions.[3]
- The lesion can weaken the vessel and can further can lead to:
- Obstruction
- Ischemia and infarction
- Rupture
- Hemorrhage
- The lesion can weaken the vessel and can further can lead to:
- One hypothesis is that this condition is caused by antibodies against HBV, via a type IIII hypersensitivity reaction.
- Hepatitis C associated polyarteritis nodosa is the most common type among the hepatitis C associated vasculitis and has a severe clinical presentation.[4]
- Clinical responses to immunosuppressive therapy suggest that immunological mechanisms play an active pathogenic role.
- Due to inflammation of the medium to small sized vessels in PAN and the presence of impaired endothelial function, there could be direct endothelial cell activation and damage resulting from proinflammatory cytokines or antibodies (anti-endothelial cells antibodies).
- These anti-endothelial cells antibodies in turn stimulate greater production of cytokines and adhesion molecules potentiating the inflammation causing more damage to the vessels [5].
Genetics
Associated Conditions
The following conditions are associated with the development of polyarteritis nodosa:
- Hepatitis B infection
- Hepatitis C infection
References
- ↑ Stone JH (October 2002). "Polyarteritis nodosa". JAMA. 288 (13): 1632–9. PMID 12350194.
- ↑ Stone JH (October 2002). "Polyarteritis nodosa". JAMA. 288 (13): 1632–9. PMID 12350194.
- ↑ Colmegna I, Maldonado-Cocco JA (August 2005). "Polyarteritis nodosa revisited". Curr Rheumatol Rep. 7 (4): 288–96. PMID 16045832.
- ↑ Saadoun D, Terrier B, Semoun O; et al. (2011). "Hepatitis C virus-associated polyarteritis nodosa". Arthritis Care Res (Hoboken). 63 (3): 427–35. doi:10.1002/acr.20381. PMID 20981809. Unknown parameter
|month=ignored (help) - ↑ Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ; et al. (2003). "Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa". Ann Rheum Dis. 62 (2): 162–7. PMC 1754444. PMID 12525387.